European Urology Open Science

Journal Information
ISSN : 26661683
Current Publisher: Elsevier BV (10.1016)
Total articles ≅ 1,785
Current Coverage
SCIE
Filter:

Latest articles in this journal

Johnathan A. Khusid, William M. Atallah, Natasha Kyprianou, Mantu Gupta
Published: 8 August 2020
European Urology Open Science; doi:10.1016/j.euros.2020.07.006

Ejun Peng, Ding Xia, Wenxi Gao, Ying Zhan, Huan Yang, Xiaoqi Yang, Hua Xu, Xiaoling Qu, Jie Sun, Shaogang Wang, et al.
Published: 30 July 2020
European Urology Open Science; doi:10.1016/j.euros.2020.07.004

Abstract:
Emerging asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were detected and multiple cases were found to be SARS-CoV-2 positive again, which raised an alarm for the patients hospitalized after the coronavirus disease 2019 (COVID-19) pandemic. We investigated the risk and prevention of hospital transmission of SARS-CoV-2 to hospitalized urological patients. This is a retrospective study of 319 hospitalized urological patients enrolled between April 20, 2020 and May 11, 2020 from two tertiary hospitals in Wuhan, China. Chest computed tomography (CT) images, nucleic acid tests (NATs), and serum antibody were examined at the outpatient department and 1 wk after admission for all patients. The chest CT images, NATs, serum antibody results, and clinical data were collected and analyzed. None of the 319 patients was found to be SARS-CoV-2 NAT positive. Ten and four patients were detected to be immunoglobulin (Ig)G and IgM positive, respectively. The chest CT features of 116 patients showed abnormal lung findings. During the 1-wk isolation, one patient initially being IgG positive only was found to be IgM positive, and another initially IgM-positive patient had a rising IgG level. Through risk assessment, we identified seven patients with very high and high risk for hospital transmission, and delayed the surgery while maintaining close follow-up. Five intermediate-risk patients were operated on successfully under paravertebral block or epidural anesthesia to avoid opening the airway with endotracheal intubation. The remaining 104 low-risk and 203 normal patients underwent normal surgery. Of the 319 patients, seven were identified as very high and high risk, which reinforced the importance of epidemic surveillance of discharged COVID-19 patients and asymptomatic infections. Five intermediate-risk patients were operated on successfully under regional anesthesia. Our experience of risk assessment and management practice may provide a strategy to prevent severe acute respiratory syndrome coronavirus 2 transmission to hospitalized urological patients after the coronavirus disease 2019 (COVID-19) pandemic.
Juan Morote, Imma Comas, Roser Ferrer, Lucas Regis, Anna Celma, Anna Santamaría, Jacques Planas, Enrique Trilla
Published: 1 July 2020
European Urology Open Science, Volume 19, pp 24-26; doi:10.1016/j.euros.2020.06.002

Zachary Dovey, Nihal Mohamed, Yasmine Gharib, Parita Ratnani, Nada Hammouda, Sujit S. Nair, Dimple Chakravarty, Stanislaw Sobotka, Anna Lantz, Peter Wiklund, et al.
Published: 1 July 2020
European Urology Open Science, Volume 20, pp 1-11; doi:10.1016/j.euros.2020.05.005

Abstract:
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has resulted in a global health emergency, the like of which has never been seen before. Prostate cancer (PCa) services across the globe have been on hold due to changing medical and surgical priorities. There is also epidemiological evidence that PCa patients have increased incidence and mortality from SARS-CoV-2 infection due to gender differences, age, and higher propensity for risk factors (eg, respiratory disease, obesity, hypertension, and smoking status). To contribute to the emerging body of knowledge on the risks of SARS-CoV-2 infection to PCa patients and, in the face of PCa treatment delays, provide evidence-based recommendations for ongoing management of specific PCa patient groups. A literature search was performed using all sources (MEDLINE, EMBASE, ScienceDirect, Cochrane Libraries, and Web of Science) as well as the media to harness emerging data on the SARS-CoV-2 pandemic and its influence on PCa. Eligibility criteria were originality of data and relevance to PCa management. The authors note that during these unprecedented times, retrospective data are constantly being updated from multiple sources globally. A total of 72 articles and data sources were found initially. Owing to repetition, lack of originality, or nonrelevance, six articles were rejected, leaving 23 retrospective studies, seven basic science research articles, 15 societal and journal guidelines, and 21 epidemiological data sources, from countries at different stages of SARS-CoV-2 pandemic. These were analyzed qualitatively to produce evidence-based guidelines for the management of PCa patients at different stages of the patient journey, with strategies to reduce the risk of viral spread. PCa patients may have an increased risk of SARS-CoV-2 infection as well as morbidity and mortality if infected. Once appropriately triaged, and to reduce viral spread, PCa patients can have surveillance by telemedicine, and institute lifestyle changes and social quarantining measures. If risk stratification suggests that treatment should be planned, androgen deprivation therapy can be started, or potentially surgery or radiation therapy is possible on a case-by-case basis. Prostate cancer patients can be followed up remotely until the severe acute respiratory syndrome coronavirus 2 pandemic resolves, but higher-risk cases may have treatment expedited to limit any negative impact on prostate cancer outcomes.
D. Maffei, M. Paciotti, F. Regis, N. Frego, P. Diana, V. Fasulo, R. Peschechera, A. Benetti, M. Lazzeri, R. Hurle, et al.
Published: 1 July 2020
European Urology Open Science, Volume 19; doi:10.1016/s2666-1683(20)34173-2

P.K. Chiu, J.Y. Teoh, S.Y. Lau, C.H. Yee, K.L. Lo, K.M. Li, S.Y. Li, S.W. Kwok, C.K. Chan, S.M. Hou, et al.
Published: 1 July 2020
European Urology Open Science, Volume 19; doi:10.1016/s2666-1683(20)34201-4

P.R. Ryan, U. Haroon, R. Keenan, B. Mc Guire
Published: 1 July 2020
European Urology Open Science, Volume 19; doi:10.1016/s2666-1683(20)34204-x

M.J. Connor, D. Eldred-Evans, F. Hosking-Jervis, E. Bass, D. Reddy, M. Bertoncelli Tanaka, H. Bhola-Stewart, C. Khoo, W. Maynard, T.T. Shah, et al.
Published: 1 July 2020
European Urology Open Science, Volume 19; doi:10.1016/s2666-1683(20)34162-8

M.M. Huang, Z.T. Su, J.G. Cheaib, M.J. Biles, M.E. Allaf, P.M. Pierorazio
Published: 1 July 2020
European Urology Open Science, Volume 19; doi:10.1016/s2666-1683(20)34106-9

T. Van Doeveren, M. Van Der Mark, P.J. Van Leeuwen, J.L. Boormans, K.K.H. Aben
Published: 1 July 2020
European Urology Open Science, Volume 19; doi:10.1016/s2666-1683(20)34080-5

Back to Top Top